<DOC>
	<DOC>NCT02993926</DOC>
	<brief_summary>The purpose of this study is to assess long-term safety and efficacy of leuprorelin in the treatment of Central Precocious Puberty (CPP) in Chinese participants.</brief_summary>
	<brief_title>A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty Among Chinese Participants</brief_title>
	<detailed_description>The drug being tested in this study is called leuprorelin. Leuprorelin is being researched to treat children who have CPP. This study will look at long term safety and efficacy of leuprorelin in the treatment of Chinese participants with CPP. The study will enroll approximately 300 patients. Participants will be assigned to following groups based on the dose received per body weight: - Leuprorelin low dose group - Leuprorelin high dose group All participants who have received leuprorelin 30 μg/kg to &lt;90 μg/kg or 90 μg/kg to 180 μg/kg per body weight, injection, subcutaneously, every 4 weeks up to at least 9 months during the index period from September 1st 1998 to September 30th 2017 will be observed. This multi-center trial will be conducted in China. Data will be collected over period of 19 months.</detailed_description>
	<mesh_term>Puberty, Precocious</mesh_term>
	<criteria>1. Has diagnosis of CPP. 2. Has been treated with leuprorelin (Enantone) for at least 9 months, under stable dose of either high dose (≥ 90 μg/kg up to 180 μg/kg) or low dose (&lt; 90 μg/kg down to 30 μg/kg). 3. Has initiated and completed treatment during the index period from September 1st 1998 to September 30th 2017. 4. Have the following information prior to treatment and at least one record after initiation of the treatment in the medical records: height, weight, secondary sexual characteristics based on Tanner staging, estradiol or testosterone level, follicle stimulating hormone and luteinizing hormone level, pelvic ultrasonography in female, and testicular volume for male. 1. Has been treated with leuprorelin for conditions other than CPP. 2. Has used other gonadotropin releasing hormone analogs (GnRHa) products prior to initiation of leuprorelin therapy or switched to other GnRHa product during treatment period. 3. CPP participants with identified etiology, such as brain tumor or cranial irradiation.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>9 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>